Publications by authors named "N van den Berghe"
Adeno-associated virus (AAV) is a non-pathogenic virus used as a delivery vehicle to transfer therapeutic genes into patients. Accurate quantification of AAV genome copy number in vector preparations is essential for bioprocess optimization and dosage calculation in both preclinical and clinical studies of AAV-based gene therapy products. Currently, a consensus protocol for AAV viral genome titration is lacking.
View Article and Find Full Text PDFBackground: Since not all Crohn's disease (CD) patients respond adequately to ustekinumab therapy, biomarkers could aid to monitor treatment response and optimize therapeutic outcomes.
Objectives: To explore the dynamics of serum biomarker concentrations to monitor the response to ustekinumab treatment in CD patients.
Design: Retrospective, exploratory study to evaluate concentrations of serum cytokines and acute phase proteins and their relation to endoscopic remission in CD patients during ustekinumab treatment.
Article Synopsis
- Treatment with neutralizing monoclonal antibodies (mAbs) is important for managing COVID-19, but there's a challenge as some SARS-CoV-2 variants can evade these treatments.
- Researchers discovered six new mAbs from a convalescent COVID-19 patient, effective against various SARS-CoV-2 strains, including omicron.
- Two specific mAbs, 3E6 and 3B8, showed strong effectiveness in hamsters for treating infections and demonstrated potential for gene-based delivery to enhance their production and effectiveness against viral variants.
Background And Aims: Some patients with ulcerative colitis [UC] do not respond to vedolizumab treatment despite adequate drug exposure in serum. This study aimed to investigate vedolizumab in tissue and questioned whether insufficient tissue exposure could explain non-response in UC patients with adequate serum vedolizumab concentrations.
Methods: A paired serum sample and colonic mucosal biopsy was collected from 40 UC patients [20 endoscopic responders, 20 non-responders] at week 14 of vedolizumab treatment.